title: Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
abstract: In two recent clinical trials, a vaccine containing herpes simplex virus (HSV) type 2 glycoprotein D (gD2) and a novel adjuvant AS04 comprising alum (Al) and 3-deactylated monophosphoryl lipid A (3-dMPL) afforded HSV-seronegative women significant protection against HSV-2 genital disease (vaccine efficacy, 73% in study 1 and 74% in study 2) and limited protection against infection (46% in study 1 and 39% in study 2). In the present report, studies in the guinea pig model investigated the protection afforded by gD2/AS04 against HSV-1 and HSV-2 genital herpes and investigated whether immunization could prevent or reduce recurrent disease in guinea pigs that developed mucosal infection. Immunization with gD2/AS04 conveyed nearly complete protection against primary disease with either virus but did not prevent mucosal infection. Guinea pigs immunized with gD2/AS04 were significantly better protected against recurrent disease than were guinea pigs immunized with a gD2/Al vaccine, which suggests that inclusion of 3-dMPL improved protection against latent infection.
authors.affiliation: Division of Infectious Diseases, Children's Hospital Medical Center, Cincinnati, Ohio, USA. nibourne@utmb.edu
authors.forename: Nigel
authors.initials: N
authors.lastname: Bourne
authors.forename: Fernando J
authors.initials: FJ
authors.lastname: Bravo
authors.forename: Myriam
authors.initials: M
authors.lastname: Francotte
authors.forename: David I
authors.initials: DI
authors.lastname: Bernstein
authors.forename: Martin G
authors.initials: MG
authors.lastname: Myers
authors.forename: Moncef
authors.initials: M
authors.lastname: Slaoui
authors.forename: Lawrence R
authors.initials: LR
authors.lastname: Stanberry
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D006168:Guinea Pigs; D006558:Herpes Genitalis / Q000517:prevention & control* / Q000821:virology; D006561:Herpes Simplex / Q000517:prevention & control*; D022301:Herpes Simplex Virus Vaccines / Q000008:administration & dosage*; D018259:Herpesvirus 1, Human; D018258:Herpesvirus 2, Human / Q000276:immunology; D055502:Secondary Prevention; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage; D014759:Viral Envelope Proteins / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D022301:Herpes Simplex Virus Vaccines; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; C040570:glycoprotein D-herpes simplex virus type 2